Allergan's Botox, or onabotulinumtoxin A, has been approved by the FDA for use in patients with overactive bladder who can't take or don't improve with anticholinergics. The approval was based on results of two clinical studies showing that Botox reduced the frequency of incontinence and urination compared with placebo.
FDA expands use of Allergan's Botox to include overactive bladder
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||